Given that the early studies showed limited clinical efficacy of pan-RAF monotherapy, mechanisms of resistance were elucidated using melanoma cells that were treated with and ultimately developed resistance to belvarafenib, a pan-RAF inhibitor. This evidence concerns the gene RAF1 and melanoma.